Human recombinant tissue-plasminogen activator (alteplase): why not use the ‘human' dose for stroke studies in rats?

Since a pioneer work that has shown in vitro that the rat's fibrinolytic system is 10-fold less sensitive to recombinant tissue-plasminogen activator (rtPA) than the human system, most preclinical studies are performed with 10 instead of 0.9 mg/kg rtPA (the clinical dose in stroke patients). In...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Haelewyn, Benoît, Risso, Jean-Jacques, Abraini, Jacques H
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2010
Pynciau:
Brief Communication
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2949192/
https://ncbi.nlm.nih.gov/pubmed/20216551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jcbfm.2010.33
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg